C4 Therapeutics presents new biomarker data from cemsidomide trials
C4 Therapeutics said it presented new biomarker data from its phase 1 cemsidomide trial with dexamethasone and phase 1b trial with elranatamab at the IMS annual meeting.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.